Results 31 to 40 of about 5,684 (155)

Extrapolation of Survival Benefits in Patients with Transthyretin Amyloid Cardiomyopathy Receiving Tafamidis: Analysis of the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial

Cardiology and Therapy, 2020
Introduction In the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT; ClinicalTrials.gov number NCT01994889), tafamidis reduced the risk of all-cause mortality in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) by 30 ...
Benjamin Li, Jose Alvir, Michelle Stewart   +2 more
doaj   +1 more source

Tafamidis Efficacy Among Octogenarian Patients in the Phase 3 ATTR-ACT and Ongoing Long-Term Extension Study. [PDF]

, 2023
Background Tafamidis was approved to treat patients with transthyretin amyloid cardiomyopathy (ATTR-CM) on the basis of findings from the phase 3 Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT).
Witteles, Ronald, Sekijima, Yoshiki, Sultan, Marla B., Perfetto, Federico, García Pavía, Pablo, Gundapaneni, Balarama, Hanna, Mazen, Garcia-Pavia, Pablo, Sultan, Marla B   +8 more
core   +1 more source

Cardiac Biomarker Change at 1 Year After Tafamidis Treatment and Clinical Outcomes in Patients With Transthyretin Amyloid Cardiomyopathy

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Although tafamidis treatment improves prognosis in patients with wild‐type transthyretin amyloid cardiomyopathy, an optimal surrogate marker monitoring its therapeutic effect remains unclear.
Naoto Kuyama, Seiji Takashio, Tetsuya Oguni, Masahiro Yamamoto, Kyoko Hirakawa, Masanobu Ishii, Shinsuke Hanatani, Seitaro Oda, Yasushi Matsuzawa, Hiroki Usuku, Eiichiro Yamamoto, Toshinori Hirai, Mitsuharu Ueda, Kenichi Tsujita   +13 more
doaj   +1 more source

Tafamidis polyneuropathy amelioration requires modest increases in transthyretin stability even though increases in plasma native TTR and decreases in non-native TTR do not predict response

, 2022
TTR aggregation causes hereditary transthyretin (TTR) polyneuropathy (ATTRv-PN) in individuals with destabilised TTR variants. ATTRv-PN can be treated with ligands that bind TTR and prevent aggregation.
Evan T. Powers (1313592), Cecília Monteiro (13888010), Joana Fernandes (587970), Jeffery W. Kelly (185563), Marta Novais (1313604), João Anselmo (8262432), Teresa Coelho (1313583), Carla Rodrigues (1280259), David L. Powers (13888016), Jaleh S. Mesgarzadeh (13888013)   +9 more
core   +1 more source

Transthyretin amyloid cardiomyopathy: Literature review and red‐flag symptom clusters for each cardiology specialty

ESC Heart Failure, Volume 12, Issue 2, Page 955-967, April 2025.
Abstract Wild‐type transthyretin amyloid cardiomyopathy (ATTRwt‐CM) is a progressive and infiltrative cardiac disorder that may cause fatal consequences if left untreated. The estimated survival time from diagnosis is approximately 3–6 years. Because of the non‐specificity of initial symptom manifestation and insufficient awareness among treating ...
Yasuhiro Izumiya, Toru Kubo, Jin Endo, Seiji Takashio, Masatoshi Minamisawa, Jun Hamada, Tomonori Ishii, Hajime Abe, Hiroaki Konishi, Kenichi Tsujita   +9 more
wiley   +1 more source

Survival in a Contemporary, Real-World Cohort of Patients with Mixed-Phenotype Transthyretin Amyloid Cardiomyopathy Treated with Tafamidis: An Analysis from THAOS

Cardiology and Therapy
Introduction Tafamidis is approved to treat transthyretin amyloid cardiomyopathy (ATTR-CM). Many patients with ATTR-CM present with a mixed phenotype of both cardiac and neurologic symptoms, but real-world effectiveness studies of tafamidis in this ...
Jonas Wixner, Angela Dispenzieri, Leslie Amass, Martin Carlsson, Steve Riley, Evan Powers, Jeffery W. Kelly, the THAOS investigators   +7 more
doaj   +1 more source

Prevalence of transthyretin cardiac amyloidosis in undifferentiated heart failure with preserved ejection fraction

ESC Heart Failure, Volume 12, Issue 2, Page 1176-1182, April 2025.
Abstract Aims Transthyretin amyloid cardiomyopathy (ATTR‐CM) is an increasinglyrecognized cause of heart failure with preserved ejection fraction (HFpEF), which may be diagnosed non‐invasively using 99mTc 3,3‐diphosphono‐1,2‐propanodicarboxylic acid (DPD) scintigraphy‐based diagnostic criteria.
L. Healy, G. Giblin, A. Gray, N. Starr, L. Murphy, D. O'Sullivan, E. Kavanagh, C. Howley, C. Tracey, E. Morrin, A. McDaid, A. Clarke, J.O. O'Neill, E. Joyce, M. O'Connell, N. G. Mahon   +15 more
wiley   +1 more source

Phosphoryl Radicals from Trivalent Iminyl Phosphines: A Photocatalytic Approach to N‐Phosphoryl Azetidines

Angewandte Chemie, Volume 138, Issue 29, 13 July 2026.
Photochemically generated phosphoryl radicals from iminyl phosphines enable strain‐release addition to azabicyclobutanes, providing access to elusive N‐phosphoryl azetidines. Combined experimental, computational, and EPR studies reveal an unconventional water‐assisted photoredox pathway.
Chandu G. Krishnan, Gabriel Cormier, Stefano A. Serapian, Marco Bortolus, Luca Dell'Amico   +4 more
wiley   +2 more sources

Pharmacological Interventions for Hereditary Transthyretin-Related Amyloidosis With Polyneuropathy: Systematic Review and Network Meta-Analysis. [PDF]

Eur J Neurol
We conducted a systematic review and network meta‐analysis on pharmacological therapies for ATTRv‐PN. Gene‐silencing therapies were more efficacious than stabilizers for neurological and quality‐of‐life outcomes; there were no differences in serious adverse events.
Duarte GS, Machado TLGN, Rodrigues FB, Conceção I, Pareyson D, da Costa JNMPG, Task Force of the EAN/PNS Joint Guideline for the Management of Neurological Manifestations in Hereditary Transthyretin Amyloidosis.   +6 more
europepmc   +2 more sources

Eficacia y costo-efectividad de tafamidis para el tratamiento de la cardiopatía por amiloidosis transtirretina

Revista Colombiana de Cardiología
Introducción: El uso de tafamidis ha sido aprobado para el manejo de la miocardiopatía por amilodosis transtirretina (CM-ATTR). Sin embargo, su alto costo obliga a evaluar su eficacia y costoefectividad.
Juan C. Díaz, Julián M. Aristizábal, Oriana Bastidas, Jorge E. Marín, César D. Niño, Mauricio Duque   +5 more
doaj   +1 more source